Enlarged Prostate

BPH vs. Prostate Cancer: What’s the Difference?

Both conditions affect the prostate and can involve urinary changes, but BPH is benign growth while prostate cancer is uncontrolled growth of malignant cells. Symptoms alone cannot reliably tell them apart.

By the Vitality Review Center Editorial Team

Last updated: September 15, 2026

Quick answer

Benign prostatic hyperplasia (BPH) is not prostate cancer, and BPH does not turn into cancer. BPH is noncancerous growth that often compresses the urethra and causes urinary symptoms. Prostate cancer begins when cells in the prostate grow out of control; early disease often causes no symptoms.

The two conditions can occur in the same man and may produce overlapping symptoms. A PSA result cannot confirm either diagnosis by itself because BPH, inflammation, infection, medications, procedures, age, and cancer can all affect PSA. Medical history, examination, trends in test results, imaging, and sometimes biopsy are used to determine what is happening.

What BPH and prostate cancer are

Benign prostatic hyperplasia

BPH is noncancerous enlargement of the prostate. It becomes more common with age and usually develops in tissue around the urethra. Because the prostate surrounds part of the urethra below the bladder, growth in this area can narrow the urinary channel or change how the bladder works.

BPH may cause a weak or interrupted stream, difficulty starting, urgency, frequency, nighttime urination, dribbling, or the feeling that the bladder has not emptied. Prostate size and symptom severity do not always match: a large prostate can cause few symptoms, while a smaller enlargement may be bothersome.

Prostate cancer

Prostate cancer develops when malignant cells grow in prostate tissue. Many prostate cancers grow slowly, but some are aggressive and can spread beyond the gland. Cancer commonly begins in the outer portion of the prostate, away from the urethra, which helps explain why early prostate cancer often does not affect urination.

If cancer grows or spreads, possible symptoms can include urinary changes, blood in urine or semen, erectile difficulties, persistent pain in the back, hips, or pelvis, or unexplained weight loss. These symptoms are not specific to cancer, and their presence does not establish a diagnosis.

If you want a simple anatomy refresher before continuing, see What Is the Prostate and What Does It Do?

BPH vs. prostate cancer at a glance

Feature	BPH	Prostate cancer
Type of condition	Benign, noncancerous tissue growth	Malignant cell growth
Typical location	Often develops around the urethra in the transition zone	Often begins in the peripheral zone, although it can arise elsewhere
Early symptoms	Urinary symptoms are common, though some men have none	Often no symptoms in early stages
Can it spread?	No. BPH does not invade other organs or metastasize	Yes. Aggressive or advanced cancer may spread
PSA	May be elevated because benign prostate tissue also produces PSA	May be elevated, but a normal or lower result does not completely rule cancer out
How it is confirmed	History, examination, urine and blood tests, and selected urinary or imaging tests	Risk assessment and diagnostic testing; biopsy is used to establish a tissue diagnosis when indicated
Treatment goal	Relieve symptoms, improve emptying, and prevent complications	Monitor low-risk disease when appropriate or control/remove cancer based on risk and stage

How the symptoms compare

Weak flow, hesitancy, frequency, urgency, nocturia, and incomplete emptying are strongly associated with BPH—but they can also result from bladder problems, infection, prostatitis, medication effects, urethral narrowing, neurologic conditions, or prostate cancer.

The reverse is equally important: having no urinary symptoms does not rule out prostate cancer. Screening is intended to look for potentially important cancer before symptoms appear, while diagnostic evaluation investigates an existing symptom, examination finding, or abnormal test.

Symptoms cannot diagnose the cause

A weak stream does not mean cancer, and a comfortable urine stream does not guarantee that cancer is absent. New, persistent, or worsening urinary changes should be evaluated in context rather than self-diagnosed. Review common early BPH patterns in First Signs of an Enlarged Prostate.

Symptoms more typical of urinary obstruction

Difficulty starting urination
Weak, slow, or interrupted urine stream
Straining to urinate
Dribbling after urination
Feeling that the bladder has not emptied

Changes that deserve prompt evaluation

Visible blood in the urine or semen
Persistent bone, back, hip, or pelvic pain without a clear explanation
Unexplained weight loss or increasing fatigue
New erectile or ejaculatory problems
Rapidly worsening urinary symptoms

These findings can have causes other than cancer, but they should not be ignored.

What a PSA test can—and cannot—tell you

Prostate-specific antigen (PSA) is a protein produced by prostate tissue. A PSA blood test can contribute to prostate cancer screening and to the evaluation or monitoring of prostate conditions. It is prostate-specific, not cancer-specific.

PSA can rise because of prostate cancer, BPH, prostatitis, urinary infection, recent prostate procedures, and other factors. Age, prostate volume, medications, and the pattern of change over time also matter. Finasteride and dutasteride lower PSA and require adjusted clinical interpretation.

An elevated PSA does not automatically mean cancer, while a result below a particular threshold cannot guarantee that cancer is absent. A clinician may repeat the test, look at prior values, address temporary causes, or use additional risk-assessment tools before recommending MRI or biopsy.

Screening and diagnosis are different

Screening is testing a person who does not have symptoms to look for cancer before it causes problems. Diagnostic testing follows a symptom, abnormal examination, elevated PSA, or other concern. Screening has potential benefits and harms—including false-positive results, biopsy complications, and finding a cancer that might never have caused harm—so it should involve an informed discussion rather than a universal one-size-fits-all decision.

How doctors distinguish BPH from prostate cancer

No single symptom or initial test provides the full answer. The evaluation is usually built in stages:

Medical and family history. The clinician reviews urinary and sexual symptoms, duration, medications, infections, previous PSA results, family history, and personal risk factors.
Physical examination. A digital rectal exam may assess prostate size, symmetry, texture, tenderness, or a suspicious firm area. A normal examination cannot exclude all cancer.
Urine and blood testing. Urinalysis may identify blood or infection. PSA may contribute to risk assessment but does not diagnose cancer by itself.
Urinary-function testing. Post-void residual measurement, urine-flow testing, ultrasound, cystoscopy, or urodynamic studies may be used when obstruction or bladder dysfunction needs clarification.
Cancer-focused assessment when indicated. Repeat PSA, additional biomarkers, risk calculators, prostate MRI, and biopsy may be considered according to the overall level of concern.

A biopsy removes small tissue samples for examination and can confirm whether cancer cells are present. Not every elevated PSA requires immediate biopsy, and not every man with urinary symptoms needs cancer imaging. The sequence depends on risk, results, preferences, and clinical judgment.

For a detailed walkthrough of the BPH evaluation, read How Is an Enlarged Prostate Diagnosed?

Risk factors, causation, and coexistence

BPH and prostate cancer both become more common with age, so they are often found in the same age group and may coexist. That overlap can create the impression that one condition caused the other.

BPH does not transform into prostate cancer. They are different biological processes. A man being treated for BPH can still develop prostate cancer independently, which is why treatment of urinary symptoms does not replace appropriate discussions about cancer risk or screening.

Factors associated with BPH

Increasing age
Family history of BPH
Physical inactivity
Obesity, type 2 diabetes, cardiovascular disease, and certain other health conditions

Factors associated with prostate cancer

Increasing age
Family history of prostate cancer, especially in close relatives or at younger ages
Inherited genetic variants or a family pattern of certain cancers
Black ancestry; Black men in the United States have higher incidence and mortality

Risk factors do not determine an individual diagnosis. They help guide when screening conversations may begin and how test results are interpreted.

How treatment differs

BPH treatment is based mainly on symptom burden, bladder emptying, prostate anatomy, complications, and quality of life. Options include watchful waiting, lifestyle adjustments, alpha blockers, 5-alpha-reductase inhibitors, tadalafil, minimally invasive therapies, and surgery. Explore the differences in BPH Treatment Options.

Prostate cancer management depends on whether cancer is confirmed and, if so, its grade, stage, PSA pattern, imaging, genomic or other risk information, overall health, and preferences. Options may include active surveillance, surgery, radiation, hormone-based treatment, systemic therapies, or combinations.

The phrase active surveillance can appear in both areas but does not mean exactly the same thing. In BPH, monitoring generally tracks symptoms and urinary complications. In confirmed low-risk prostate cancer, active surveillance follows a structured cancer-monitoring protocol intended to avoid or delay treatment while watching for signs of progression.

When to seek medical care

Arrange a medical evaluation for new or persistent urinary symptoms, visible blood in urine or semen, unexplained pelvic or bone pain, recurrent urinary infections, or a concerning PSA or examination result.

Seek urgent care if you cannot urinate at all, have severe lower-abdominal or urinary-tract pain, pass blood clots that interfere with urination, or have painful and frequent urination accompanied by fever and chills.

Frequently asked questions

Can BPH turn into prostate cancer?

No. BPH is benign growth and does not transform into prostate cancer. However, both conditions become more common with age and can occur in the same person, so BPH treatment does not eliminate the need for appropriate cancer-risk discussions.

Can an enlarged prostate raise PSA without cancer?

Yes. Benign prostate tissue produces PSA, so BPH can contribute to a higher result. Infection, inflammation, procedures, medications, age, and cancer can also affect PSA. The value must be interpreted in context and sometimes repeated.

Does a normal PSA rule out prostate cancer?

No PSA value can completely rule out cancer. Risk depends on the result, change over time, age, prostate size, medications, family history, examination findings, and other factors. A clinician can determine whether additional evaluation is appropriate.

Which causes more urinary symptoms: BPH or prostate cancer?

BPH commonly causes urinary obstruction because it usually grows around the urethra. Early prostate cancer often causes no symptoms. Advanced or strategically located cancer can cause urinary changes, which is why symptoms cannot establish the diagnosis.

Can a digital rectal exam tell the difference?

It can provide useful clues. BPH may feel enlarged and smooth, while a firm, irregular, or nodular area may raise concern. However, many cancers cannot be felt, and an examination alone cannot confirm or exclude cancer.

Is a biopsy needed to diagnose BPH?

Usually not. BPH is generally assessed through symptoms, examination, urine and blood testing, and selected urinary or imaging tests. A biopsy may be recommended when the evaluation raises concern for prostate cancer.

Vitality Review Center